Proveris Scientific Appoints Daniel Tereau as President and Chief Executive Officer

Veteran life sciences executive brings more than two decades of leadership in strategy, growth and corporate development to lead the next phase of Proveris’ evolution

HUDSON, Mass., September 9, 2026 — Proveris Scientific, a leading provider of instrumentation and services that advance the science of aerosol and spray products and an independently managed portfolio company of Investindustrial Growth III Holdings S.à r.l. (“Investindustrial”), announces the appointment of Daniel Tereau as President and Chief Executive Officer, effective September 1, 2026.

Tereau brings more than two decades of executive leadership across life sciences, diagnostics, healthcare and technology, with a track record spanning growth strategy, mergers and acquisitions, commercialization and business transformation. He has held senior leadership roles at Revvity, Novartis Consumer Health, Thermo Fisher Scientific and GE Healthcare, where he led major acquisitions, portfolio transformation and commercial growth initiatives that generated more than $2 billion in revenue growth.

As part of the leadership transition, Dino Farina will move from Chief Executive Officer to Chief Technology Officer, where he will focus on technology, product innovation and the company’s long-term technical strategy. Chip Leveille will move from President to Executive Advisor to the CEO and Board, continuing to support Proveris on strategic initiatives while expanding his work with boards, companies and entrepreneurial ventures.

“Dan brings extensive experience leading and growing businesses across the life sciences sector, together with a strong understanding of strategy, technology and global markets,” said Dino Farina, Chief Technology Officer and founder of Proveris. “Proveris has built a distinctive position through its scientific expertise, specialized technologies and long-standing customer relationships across the industry. We are pleased to welcome Dan as President and CEO and look forward to working with him and our partner Investindustrial as Proveris enters its next stage of growth.”

Tereau joins Proveris as the company continues to build on its established position in orally inhaled and nasal drug product development and testing, supporting pharmaceutical companies and device developers with specialized instrumentation, laboratory services and scientific expertise.

Daniel Tereau, President and Chief Executive Officer of Proveris Scientific, said “Proveris has built an impressive business on deep scientific knowledge, highly specialized technology and a close understanding of its customers. I am excited to join the company and work with the team to build on that foundation. There is significant opportunity to expand our capabilities, strengthen our global presence and continue developing solutions that help customers address increasingly complex challenges in drug and device development.”

Tereau holds an MBA in Strategy and Finance from Yale University, where he was a Sloan Fellow, and a JD from Wayne State University Law School. He has also completed executive education in artificial intelligence at MIT and management development at GE Crotonville.  He also serves on the faculty of the AI-Driven Leadership Program at Brandeis University’s Rabb School of Graduate Studies, where he teaches graduate-level coursework on the application of artificial intelligence to business decision-making and innovation.

For further information please contact

 

Proveris Scientific

Joanne Mather, Sr. Director of Marketing
jmather@proveris.com

Investindustrial

Jenna Ward, Global Head of Communications
jward@investindustrial.com

About Proveris Scientific

Proveris Scientific advances the science of respiratory drug delivery products by driving new technology development for high-performance spray characterization, capture and analysis. With customer success as its central motivating force, Proveris serves a global customer base with complete solutions spanning product innovation, laboratory services, technical services, systems, consumables and educational training. Since its founding in 1995, the company has accelerated the development of leading spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites worldwide. Proveris systems are used by the U.S. Food and Drug Administration, China’s National Medical Products Administration (NMPA) and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and holds more than 20 issued patents on its technology. Learn more at www.proveris.com.

About Investindustrial

Investindustrial is a leading European group of independently managed investment, holding, and advisory companies with €19 billion of raised fund capital. With sustainability principles deeply embedded into the Firm’s core approach, Investindustrial has a 36-year history of providing mid-market companies with capital, industrial expertise, operational focus and global platforms to accelerate sustainable value creation and international expansion. Certain companies of the Investindustrial group are authorized by, and subject to regulatory supervision of the FCA in the United Kingdom, the CSSF in Luxembourg and the FSRA in Abu Dhabi Global Market. References to ‘Investindustrial’ are of generic nature, for ease of reading, and may refer, depending on the context, to a fund or any of its independently managed subsidiaries. Investindustrial’s investment companies act independently from each other and each Investindustrial fund. More information is available at www.investindustrial.com

Proveris Joins Investindustrial to Support Customers and Long-Term Growth

Hudson, MA, January 14, 2026 — Proveris Scientific, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced that it has been acquired by an independent subsidiary of Investindustrial, a leading European group of independently managed investment, holding, and advisory companies with a long history in the healthcare sector. Following the transaction, the company will continue to operate as an independent company.

Founded in 1990 and rooted in an industrialist family heritage, Investindustrial has 35 years of history supporting the sustainable development of leading mid-market companies on a global basis. Proveris and its founder, Dino Farina, have chosen to partner with Investindustrial to support the next phase of development after ample consideration due to the group’s extensive track record, relevant expertise in the healthcare sector, long term orientation, and shared commitment to strong corporate values.

“The partnership with Investindustrial provides us with additional resources and capabilities to drive growth and support our customers success over the long term,” said Dino Farina, CEO. “This includes investment in people, capabilities, and infrastructure, as well as the ability to pursue partnerships and acquisitions that strengthen our offering.”

For customers, Investindustrial’s investment in Proveris is expected to strengthen the company’s positioning, support continued innovation, and enhance its ability to effectively serve customers globally. With the backing of a new industrially-oriented, long-term shareholder, and building on a strong foundation and history of driving innovation at Proveris, the Company is positioned to further expand its capabilities and continue to support efficient drug development across both small and large molecule programs.

“Our focus remains the same — supporting customers with high-quality science and reliable data — now with the additional resources of a committed long-term partner to guide the next phase of business development,” said Chip Leveille, President.

About Proveris Scientific

Proveris Scientific advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, laboratory services, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris Scientific’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris unveiled expanded product portfolio with new Vereo® Spray Weigh Collect Nasal Spray System for Delivered Dose Uniformity Testing – A sneak preview at RDD 2024

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, unveiled its latest product at the annual RDD meeting at Tucson, Arizona, on May 6th, 2024.

The Vereo Spray Weigh Collect Nasal Spray System is not just a new product, it’s a pivotal advancement in product development and quality control workflows. Designed to cater to multi-dose, bi-dose, and unit-dose vertical nasal spray drug types, this system revolutionizes sample collection and precise weighing for Delivered Dose Uniformity (DDU) testing. It streamlines the entire process, yielding significant time savings and method optimization.

The Vereo Spray Weigh Collect Nasal Spray System is built upon the foundational technology of the Vereo Automated Actuator family and Viota® Software, which were introduced in the early to mid-2000s. The technology at the heart of Vereo systems expertly replicates human usage with robust, automated actuation of nasal devices. Moreover, the integration of powerful Viota software simplifies the regulatory compliance process for customers, helping them to meet stringent requirements with more ease. The synergy between the system’s advanced technology and user-friendly software ensures that the Vereo Spray Weigh Collect Nasal Spray System sets a new standard in the industry, enhancing both the development and quality assurance stages of pharmaceutical products.

The Vereo Spray Weigh Collect Nasal Spray System automates metered dose weighing and collection of up to 10 samples, all managed by a single analyst. This not only increases efficiency but also ensures consistency and accuracy across multiple samples. With the tagline “Seconds to Weight” – Get Metered Dose Weight in Seconds!,” the system highlights its rapid and precise weighing capabilities. The integrated all-in-one solution is ideal for comprehensive through-life and Delivered Dose Uniformity (DDU) testing.

Attendees of the RDD conference had the opportunity to experience a live demonstration of the Vereo Spray Weigh Collect during the exhibition sessions.

“We were excited to present the Vereo Spray Weigh Collect to our peers, partners, and potential customers at this prestigious event,” said Dino Farina, Founder and CEO of Proveris Scientific. “This product embodies our commitment to pushing the boundaries of innovation and delivering solutions that meet the evolving needs of our industry. We believe the Vereo Spray Weigh Collect will set a new standard in the Orally Inhaled and Nasal Drug Product space.”

Maria Smith, Business Development Director of Proveris Laboratories commented, “As a leading lab services organization, we’re excited to leverage the Vereo Spray Weigh Collect to improve our processes at Proveris Laboratories. This cutting-edge system will boost our throughput and cut down on lab errors, giving our analysts more time to focus on other important tasks. Viota Software’s user-friendly interface makes it easy to use while still meeting the high standards set by regulatory agencies. Taking automated testing to the next level will greatly improve our lab’s efficiency and overall performance.”

Key Features and Benefits:

  • Utilizes the industry standard Vereo Actuator technology for consistent performance.
  • Features an integrated weigh module that measures metered shot weight for nasal spray products swiftly and accurately.
  • Enables dose collection without sample loss, thanks to novel inserts designed for wide-mouth glass volumetric flasks.
  • Includes a reusable waste collector for efficient priming and fire-down tasks.
  • Accommodates up to 10 sample collection containers, allowing for streamlined content uniformity testing in a single run.
  • Compatible with multi-dose, bi-dose, and unit-dose vertical nasal spray devices.
  • Offers walkaway automated functionality, freeing up analysts to focus on other critical tasks.

This breakthrough system is set to revolutionize the way batch nasal spray release testing is conducted, offering unprecedented levels of automation and precision. It’s a game-changer for the pharmaceutical industry, providing a pathway into the future of development and regulatory testing.

The Vereo Spray Weigh Collect will be shipping in Q3 2024 – please contact your local sales rep for more information.

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris Scientific welcomes back Alyssa Rubino as Technical Data Scientist for Proveris Laboratories

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, today announced that it has increased the level of customer support by expanding its laboratory services organization with the addition of Technical Data Scientist, Alyssa Rubino.

Alyssa rejoins the Proveris Laboratories team where for years she provided guidance, not only in designing protocols that allowed complete and efficient characterization of oral and nasal devices, but also in completing data analysis to best leverage the information and accelerate the achievement of project goals. She will report to the Director of Application and Business Development for Proveris Laboratories, Maria Smith. The combination of their talents will provide a broader and more in-depth support offering.

Alyssa will be responsible for ensuring appropriate study design, compiling and analyzing analytical study data, deriving conclusions and key information, and generating reports for all contracted projects to ensure they meet internal, customer, and regulatory standards. Alyssa has more than 10 years of experience in applications engineering, product management, and operations gained from her time with industry leaders such as Tekscan, Ocular Therapeutix, and, of course, Proveris. Utilizing her knowledge, Alyssa will also help drive the implementation of new technologies into Proveris Laboratories and expand the laboratory service offering.

Alyssa holds a Bachelor of Science in Mechanical Engineering from Northeastern University and has co-authored 5 publications on the science of orally inhaled and nasal drug products.

About Proveris Scientific:

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, China NMPA (National Medical Products Administration), and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

 

Proveris Scientific names Ramesh Chand as Associate Director of rapidly growing GMP contract test business, Proveris Laboratories

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced Ramesh Chand has been named Associate Director of Proveris Scientific’s rapidly growing GMP contract test business, Proveris Laboratories.

Ramesh Chand is a scientific expert with more than 16 years of professional experience within the Orally Inhaled and Nasal Drug Product (OINDP) development community, including analytical, formulation development, process development, device selection and characterization, scale-up/technical transfer and preclinical aerosol development on both innovator and generic drug products. His work also encompasses nebulization and nose-to-brain nasal delivery of biologics. As Associate Director of Proveris Laboratories, he will oversee the day-to-day laboratory operations, ensuring quality and regulatory standards are upheld and will assist Proveris Research in introducing innovative technologies to advance inhalation science and development. His diverse expertise will shape strategic direction and will allow Proveris to expand their menu of services.

Ramesh earned his Master of Science in chemical engineering, from Missouri University of Science and Technology, which included thesis work focused on ‘Generation and Characterization of Aerosols.’ Prior to joining Proveris, he worked for Moderna Therapeutics in Cambridge, MA as the Principal Scientist of Drug Product Development (Respiratory), Amneal Pharmaceuticals, Piscataway, NJ as a Senior Research Scientist, Inhalation Product Development, Lovelace Biomedical, Albuquerque, NM as Senior Research Associate and GlaxoSmithKline, Research Triangle Park, NC as an Associate Scientist, Inhaled Product Development. With his regular contributions to research, Ramesh has co-authored more than 15 respiratory articles.

“Ramesh is a significant addition to the Proveris Laboratories team,” commented Dino Farina, CEO, Proveris Scientific. “His experience in OINDP drug development combined with his research will provide our customers access to proven expertise that will help them achieve their goals quickly and at the highest quality. In addition, he will be a key player in helping Proveris Research deliver new and innovative technologies through Proveris Labs for the advancement of inhalation science and drug development”

Ramesh added, “I am excited to join Proveris at a time when the company is rapidly advancing the test services business. Proveris is uniquely positioned in supporting OINDP development programs. I believe the addition of innovative technologies and expanded capabilities will immensely benefit customer’s respiratory drug development.”

About Proveris Scientific
Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving innovative technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris expands product portfolio with new Kinaero Cx™ pMDI Collection System for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, adds Kinaero Cx™ pMDI Collection System to its product portfolio to automate the pMDI shaking, priming, dose sample collection, and fire-down for DDU and APSD testing.

The Kinaero Cx system incorporates proven Vereo® Automated Actuator technology to precisely control product shaking, actuation parameters, and shake-to-fire timing enabling consistent dose delivery for HPLC analysis. Compliance with EU Annex 11 and US FDA 21 CFR Part 11 is ensured by the operation and data management software with technical controls for electronic records, electronic signatures, audit trails, and data/system/user traceability. As an alternative to manual operation, the system offers benefits such as minimizing both the risk of out-of-specification shots and the downtime that could result from analyst fatigue or CAPA investigations.

The Kinaero Cx system’s flexible design simplifies testing by offering a single platform for DDU and APSD sample collection. Utilizing a unique snap-fit design for the back-end adapter to both the DUSA tube and the waste collector, the system allows for easy installation and removal for sample prep when performing DDU testing. In addition, quick set up for APSD testing is achieved with a cascade impaction kit for placement and orientation of either the Anderson cascade impactor (ACI) apparatus with vertically stacked sample plates or the next generation impactor (NGI) with horizontally placed sample plates.

The Kinaero Cx system enables a fast, smooth workflow for unparalleled ease of use. Sample collection is performed in three quick and easy steps, with control provided through our intuitive software and local database for data storage. Analysts set up methods to specify shots into the dosage sampling unit apparatus (DUSA), cascade impactor throat, and waste collector locations. An on-board sensor confirms the inhaler positioning for mating inhalers of different geometries to these three locations. There is no teaching required and users can easily switch between different inhaler types using device holder inserts adapted to various inhaler geometries.

The Kinaero Cx system offers increased throughput when used alongside the Kinaero™ pMDI High Throughput Fire-Down System. The Kinaero Fire-Down System precisely automates shaking and actuation to waste of up to 10 devices simultaneously, ensuring uniform dose delivery for every shot when transitioning between the beginning, middle, and end of life stages for an inhaler device. Both systems utilize a powerful common software platform which offers all tools to ensure full regulatory compliance (FDA 21 CFR Part 11).

Proveris Scientific’s Senior Product Manager, Ian Flaherty, commented: “An aim for the product design team at Proveris is the evolution of our product portfolio to allow customers to meet complex regulatory requirements and produce consistent high quality data. Our 25-plus years of experience in the OINDP space has taught us much about the potential for automation in reducing the variability associated with inhaler testing. The Kinaero Cx takes these learnings a step further and is designed to be an accessory to our very well-known Vereo Actuator, providing another layer of automation to benefit our customers. The solution is elegant and easy to use, and the powerful software platform will meet our customer’s strict demands for ensuring data integrity and traceability.”

The Kinaero Cx system in all its functionality will be demonstrated in the Proveris workshop at the upcoming RDD 2022 conference in Orlando, Florida. Whitepapers with published data will be made available, upon request, following the workshop on May 3rd, 2022.

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris Scientific expands research team with the addition of accomplished research scientist, Prateek Nath, Ph.D.

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced Prateek Nath has joined as a research scientist in Proveris Scientific’s growing research team.

 

Prateek will perform a range of research activities to advance new technology platforms at Proveris. His focus will be to design and build a wide variety of research-grade prototypes and run experiments on these prototypes to generate proof statements for scientific hypotheses related to aerosol science, human physiology, and drug delivery. In addition, Prateek will actively participate in Proveris’s research collaborations with academic, industrial, and government organizations. 

Prateek holds a Ph.D. in solid mechanics and minors in applied mathematics and materials science from Brown University in Providence, Rhode Island. He earned his Master of Science in mechanical design and optimization from Indian Institute of Technology, Bombay, India, and his Bachelor of Science in mechanical engineering from University of Pune. Prior to joining Proveris, Prateek worked as a computational modeling engineer for Johnson and Johnson in Raynham, Massachusetts, as a research engineer for Bose Corporation in Framingham, Massachusetts, and as a postdoctoral research fellow for Oak Ridge National Laboratory in Oak Ridge, Tennessee. Prateek holds nine U.S. Patents and has authored multiple publications and conference presentations.

Proveris Scientific’s Founder and CEO, Dino Farina, commented, “I’m excited to have Prateek join the Proveris team. Prateek’s significant engineering experience from Oak Ridge National Laboratory, Bose Corporation, and J&J are perfect complements to Proveris’s advanced research focus on integrating human physiology, aerosol science, and drug delivery into better tools for predictive performance modeling of orally inhaled and nasal drug products.”

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Maria Smith appointed as Director, Application and Business Development for Proveris Laboratories

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced the appointment of Maria L. Smith, M.Sc., to the newly established role of Director, Application and Business Development for Proveris Laboratories. This is a new position focused on addressing the rapid growth of the cGMP contract test services and the introduction of new technologies. 

Maria joins Proveris with more than 14 years of CDMO experience in the development and test of orally inhaled and nasal drug products (OINDPs). She has extensive experience in spray characterization, as well as working with customers on problem resolution and compliance. She has authored 10 publications on spray characterization and is well known across the industry for her professionalism, experience, and expertise.

Maria will help drive the growth of Proveris Laboratories contract test services through the expansion of new applications and technologies. In addition, she will serve as a liaison to regulatory agencies, industry groups, and customers to educate on new technology approaches and how they can be used to support in-vitro in-vivo correlation (IVIVC) and bioequivalence (BE).   

Proveris Scientific’s President, Chip Leveille, commented, “Maria’s fourteen years of laboratory experience in spray/particulate science (nasal and oral products) with leading CDMO’s brings a deep understanding of drug development and testing as it pertains to inhalation products. She has extensive knowledge of Proveris systems and particle characterization techniques to develop and characterize aerosol and spray delivered drug devices. We are excited to have Maria on board to further establish and enhance Proveris technologies as critical approaches to drug approval and product release.”

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Proveris Laboratories announces expanded services for spray and aerosol characterization of unit-dose nasal drugs

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced the expansion of contract test services for product characterization, performance, safety, and bioequivalence testing of unit-dose nasal drugs.

Utilizing optimized hardware, Proveris Laboratories now offers the ability to perform in vitro characterization testing on unit-dose devices at multiple orientations, allowing developers to test products designed to be administered in a prone position by a physician, first responder, or caregiver. These new service offerings allow developers to not only comply with regulatory guidance, but also gain key insights early in the development process, with regards to device performance.

Proveris Scientific’s other patented technologies and methodologies allow for robust evaluation of unit-dose spray pumps, syringes, pressurized aerosol devices, and both liquid and powder formulations intended for systemic, nose-to-brain, and local delivery. cGMP-compliant and non-GMP test services include predictive modeling experiments using the Proveris by Design™ design of experiments (DoE) method, human actuation studies using Ergo™ technology, and product characterization studies performed on industry gold standard SprayVIEW® Measurement Systems. Vereo® Automated Actuators, which are at the center of most Proveris platforms, are powered by Viota® Software, including unit-dose capability to allow for proper actuation of single shot devices that often require specially tailored profiles to deliver the full dose. 

Alberto Correia, Vice President of Technical Services and Proveris Laboratories commented, “Developers of intranasal branded and generic drugs for the treatment of conditions such as drug overdose reversal and seizures will benefit from Proveris’s simple and precise setup to be able to test their products in multiple orientations, mimicking how these products will actually be administered in real-life situations. Additionally, the unit-dose configuration in our Viota software allows each device to be actuated properly using a force limited methodology ensuring full dose delivery. Force profiles generated from each actuation can help to confirm dose delivery. This is critical for unit dose devices designed for use in combatting life-threatening events such as drug overdose and seizures, as well as for potent drugs where exceeding the dosage limit is dangerous.”

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

Lynn Jordan joins Proveris as Applications Laboratory Manager

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, today announced that experienced life sciences professional Lynn Jordan has joined Proveris as Applications Laboratory Manager.

Lynn joins Proveris with more 25 years of experience in applications and bioanalytical science, laboratory services management, and technical sales at life science technology and instrumentation providers, including:  New England Nuclear, Amicon, Zymark, Waters Corporation, Perkin Elmer, and Biotage. Lynn has a reputation as a strong leader and accomplished scientist with expertise in the introduction of new assays and technologies for sample preparation, analysis, and automation in the life sciences.

In her role at Proveris, Lynn will lead the fulfillment of contract test services, working collaboratively with field sales to meet and exceed technical support standards and customer expectations. Lynn will also play an integral role in product development and R&D projects, adding a customer perspective to the functional specifications. In addition, she will contribute to the development of promotional materials, seminars, and workshop presentations.

Lynn is the author of four publications and contributed to a chapter in “Automated Solid Phase Extraction,” published by Marcel Dekker. Lynn has a bachelor’s degree in Chemistry from Russel Sage College and has completed master’s course work in Separations Sciences from Rensselaer Polytechnical Institute.

 

About Proveris Scientific

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the pharmaceutical industry to generate submission-ready data and regulatory agencies such as the US FDA and China NMPA (National Medical Products Administration). Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.